ReviewMicroorganisms2021
Obesity, Early Life Gut Microbiota, and Antibiotics.
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 53 citations in OpenAlex.
- Early-life gastrointestinal inflammation and the developing brain: Unravelling the pathways to long-term cognitive dysfunction.World journal of clinical pediatrics · 2026Review
- Human milk oligosaccharide supplementation for metabolic health and obesity: potential mechanisms, current evidence, and research priorities.World journal of pediatrics : WJP · 2026Article
- The Gut Microbiota: An Essential Component in Understanding Pediatric Obesity: A Narrative Review.Nutrients · 2026Review
- Microplastics: a potential threat to gut microbiota and antioxidant capacity of broiler chickens.Frontiers in microbiology · 2026Article
- The impact of antibiotic exposure on obesity and metabolic phenotypes via the gut microbiota.Frontiers in microbiology · 2026Review
- Hidden connection: Impact of the gut microbiota on respiratory diseases in children (Review).Molecular medicine reports · 2026Review
- The microbial guardians: Unveiling the role of gut microbiota in shaping neurodegenerative disease.IBRO neuroscience reports · 2025Review
- Assembly of the infant gut microbiome and resistome are linked to bacterial strains in mother's milk.Nature communications · 2025Article
- From Womb to Tomb: A Life-Course Perspective on the Origins of Non-communicable Diseases.Cureus · 2025Review
- Early-life gut microbiome development and its potential long-term impact on health outcomes.Microbiome research reports · 2025Review
- Electroacupuncture improves lipid metabolism via proteome and gut microbiota profiling in obese rats.American journal of translational research · 2025Article
- Lifestyle Medicine and the Microbiome: Holistic Prevention and Treatment.Integrative medicine (Encinitas, Calif.) · 2024Article
- Cardiovascular risk of dietary trimethylamine oxide precursors and the therapeutic potential of resveratrol and its derivatives.FEBS open bio · 2024Review
- Immunogenetic Aspects of Sarcopenic Obesity.Genes · 2024Review
- Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions.Life metabolism · 2023Review
- Gut Microbiota Perturbation in Early Life Could Influence Pediatric Blood Pressure Regulation in a Sex-Dependent Manner in Juvenile Rats.Nutrients · 2023Article
- Transfer of antibiotics and their metabolites in human milk: Implications for infant health and microbiota.Pharmacotherapy · 2023Review
- Early-Life Antibiotics and Childhood Obesity: Yeast Probiotics as a Strategy to Modulate Gut Microbiota.Cureus · 2023Review
- Maturational patterns of the infant gut mycobiome are associated with early-life body mass index.Cell reports. Medicine · 2023Article
- The potential links between human gut microbiota and cardiovascular health and disease - is there a gut-cardiovascular axis?Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Obesity is a major public health problem that continues to be one of the leading risk factors for premature death. Early life is a critical period of time when the gut microbiota and host metabolism are developing in tandem and significantly contribute to long-term health outcomes. Dysbiosis of the gut microbiota, particularly in early life, can have detrimental effects on host health and increase the susceptibility of developing obesity later in life. Antibiotics are an essential lifesaving treatment; however, their use in early life may not be without risk. Antibiotics are a leading cause of intestinal dysbiosis, and early life administration is associated with obesity risk. The following review explores the relevant literature that simultaneously examines antibiotic-induced dysbiosis and obesity risk. Current evidence suggests that disruptions to the composition and maturation of the gut microbiota caused by antibiotic use in early life are a key mechanism linking the association between antibiotics and obesity. Without compromising clinical practice, increased consideration of the long-term adverse effects of antibiotic treatment on host health, particularly when used in early life is warranted. Novel adjunct interventions should be investigated (e.g., prebiotics) to help mitigate metabolic risk when antibiotic treatment is clinically necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.